FluGen, Inc.
↗Madison, USA
FluGen is a clinical-stage biotechnology company focused on transforming the efficacy of vaccines for respiratory diseases, primarily influenza. The company's core technology is the M2SR (M2-deficient Single Replication) platform, a live virus vaccine that mimics a natural infection without causing illness. Unlike traditional flu shots, M2SR is delivered intranasally and stimulates mucosal, humoral, and cellular immunity, providing broader protection against drifted or mismatched viral strains.
Founded by world-renowned virologists, FluGen aims to solve the 'universal flu vaccine' challenge. Their lead candidate has demonstrated the ability to protect against highly drifted strains in human challenge trials, a feat that traditional inactivated vaccines often fail to achieve. The company is also exploring the M2SR platform as a vector for other respiratory pathogens, including COVID-19 and RSV.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$1M-$5M
Founded:2007
Ownership:private
Status:operating
FUNDING
Stage:Series A/B
Total Raised:$40.1M
Investors:Venture Investors LLC, Wisconsin Alumni Research Foundation (WARF), State of Wisconsin Investment Board, Knox LLC, National Institutes of Health (NIH), Department of Defense (DoD)
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2 (Human Challenge Completed)
Modalities:Live Attenuated Virus, Single-Replication Virus, Intranasal Vaccine
Active Trials:3
Trial Phases:Phase 1: 2 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:BARDA (Funding and development support), Department of Defense (Sponsor of human challenge trials), SGS Belgium (Clinical trial execution), University of Wisconsin-Madison (Technology origin)
COMPETITION
Position:Emerging
Competitors:Osivax (OVX836), Vivaldi Biosciences (deltaFLU), Barinthus Biotherapeutics (VTP-100), Sanofi (Fluzone HD), Moderna (mRNA-1010), Pfizer (mRNA flu programs)
LEADERSHIP
Key Executives:
Paul Radspinner - CEO & President
Pamuk Bilsel - CSO
Scientific Founders:Yoshihiro Kawaoka, Gabriele Neumann, Paul Radspinner
Board Members:Dan Stinchcomb, C. Boyd Clarke, Paul Weiss
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of FluGen, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with FluGen, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.